The Center for Cell and Gene Therapy and al., 2001; Shevach, 2000). Besides naturally occurring Department of Immunology CD4 ϩ CD25 ϩ Treg cells, other CD4 ϩ Treg cells include Baylor College of Medicine Tr-1 cells secreting IFN-␥ and IL-10, and Th3 cells se-Houston, Texas 77030 creting high levels of TGF-␤, IL-4, and IL-10 (Francois 2 Laboratory of Immunology Bach, 2003; Roncarolo and Levings, 2000; Weiner, National Institute of Allergy and 2001). Although expression of CD25 on T cells has been Infectious Diseases used as a useful marker of Treg cells, its expression is National Institutes of Health not necessarily associated with Treg cell function in that Bethesda, Maryland 20892 it is also expressed by activated, nonregulatory effector lymphocytes. Other molecules, including the TNF family molecule GITR and cytotoxic T lymphocyte antigen-4 Summary (CTLA4) may serve as markers for Treg cells (Sakaguchi et al., 2001; Wood and Sakaguchi, 2003). Recently, sev-Regulatory T cells play an important role in the mainteeral groups reported that foxp3 may serve as a potential nance of immunological self-tolerance by suppressing marker of CD4 ϩ Treg cells in mice (Fontenot et al., 2003; immune responses against autoimmune diseases and Hori et al., 2003; Khattri et al., 2003), but it is not clear cancer. Little is known, however, about the nature of whether the finding also applies to human CD4 ϩ Treg the physiological target antigens for CD4 ؉ regulatory cells. Therefore, Treg cells must be defined primarily T (Treg) cells. Here we report the identification of the according to their immunosuppressive function (von LAGE1 protein as a ligand for tumor-specific CD4 ؉ Herrath and Harrison, 2003). They inhibit other immune Treg cell clones generated from the tumor-infiltrating cell functions either directly through cell-cell contact lymphocytes (TILs) of cancer patients. Phenotypic and or indirectly through the secretion of anti-inflammatory functional analyses demonstrated that they were antimediators such as IL-10, TGF-␤, or IL-4 (Levings et al., gen-specific CD4 ؉ Treg cells expressing CD25 and 2002a; Shevach, 2002). Treg cells are demonstrated GITR molecules and possessing suppressive activity most convincingly by their ability to inhibit autoimmune on the proliferative response of naive CD4 ؉ T cells to disease development of transplant rejection in animal anti-CD3 antibody stimulation. Ligand-specific activamodels, after de novo induction in vivo or after passive tion and cell-cell contact were required for TIL102 Treg cotransfer with effector cells into suitable hosts (von cells to exert suppressive activity on CD4 ؉ effector Herrath and Harrison, 2003). cells. These findings suggest that the presence of tu-While most studies have been focused on the role of mor-specific CD4 ؉ Treg cells at tumor sites may have Treg cells in the prevention of various organ-specific a profound effect on the inhibition of T cell responses autoimmune diseases (Sakaguchi et al., 1995; Shevach, against cancer. 2000), several recent studies report an increased frequency of CD4 ϩ Treg cells in cancer patients (Liyanage Introduction et al., 2002; Woo et al., 2001). In animal models, removal of CD4 ϩ CD25 ϩ Treg cells enhances antitumor immune CD4 ϩ effector and regulatory T cells recognize peptides responses (Shimizu et al., 1999; Sutmuller et al., 2001), presented by MHC class II molecules but play distinctly implying that these cells suppress immune responses different roles in regulating host immune responses against cancer cells. However, very little is known about against cancer and other diseases (Germain, 1994; Rothe physiological target antigens recognized by CD4 ϩ senberg, 2001; Sakaguchi et al., 2001; Shevach, 2002). Treg cells in such settings. Our current knowledge of CD4 ϩ effector (helper) T cells are required for the priming the antigen specificity of CD4 ϩ Treg cells has come and maintenance of CD8 ϩ T cells, thus enhancing the largely from studies with antigen-specific TCR transoverall immune response (Houghton et al., 2001; Wang, genic animals (Apostolou et al., 2002; Curotto de Lafaille 2001). Recently, CD4 ϩ T cells were shown to be required and Lafaille, 2002; Hori et al., 2002; Maloy and Powrie, for the subsequent expansion of memory CD8 ϩ T cells 2001; Shevach, 2002). Because bulk CD4 ϩ CD25 ϩ T cell (Janssen et al., 2003; Shedlock and Shen, 2003; Sun populations may display very diverse specificities for and Bevan, 2003). Thus, identification of MHC class IIautoantigens (tissue-specific self-antigens) and tumor restricted tumor antigens capable of stimulating CD4 ϩ antigens, it has been difficult to identify the physiological T cell responses is a critical step in the development of ligands recognized by antigen-specific CD4 ϩ Treg cells. effective cancer vaccines (Wang, 2002).
ization of tumor-specific CD4 ϩ Treg cells and identifica-obtained with other T cell clones (data not shown). T cells responded to both HLA-DR13 ϩ M102 and 1495mel tu-tion of their natural ligands. Using these antigen-specific cells, we also show that cell-cell contact is required for mor cell lines, but not to DR13 ϩ EBV-transformed B cells or DR13 Ϫ cell lines. T cell reactivity against M102 tumor Treg cell mediated immune suppression. cells could be specifically blocked by a monoclonal antibody against HLA-DR, but not by one against HLA-DQ, Results HLA-DP, or MHC class I molecules ( Figure 1B) . To further determine the restriction element, we tested whether Generation of Tumor-Specific CD4 ؉ T Cell Clones A tumor-reactive TIL line (TIL102) was first established CD4 ϩ T cell clones could recognize DR3-positive or DR13-positive EBV-transformed B cells pulsed with from a fresh melanoma sample. After depletion of CD8 ϩ T cells with a bead-coated anti-CD8 antibody, we estab-M102 tumor lysates. As shown in Figure 1C , CD4 ϩ T cells responded to DR13-positive LCL-7 cells pulsed with lished CD4 ϩ T cell lines that recognized an autologous tumor cell line (M102) generated from the same tumor tumor cell lysates but recognize neither DR13-positve LCL-7 cells alone nor DR3-positive 1359EBV cells sample. To obtain tumor-reactive CD4 ϩ T cell clones, we cloned T cells (0.3 cell/well) by a limiting dilution pulsed with the same tumor cell lysates. These studies suggest that CD4 ϩ T cells recognize a tumor antigen in method in culture medium containing irradiated PBMCs (5 ϫ 10 4 cells per well in a 96-well plate), anti-CD3, anti-the context of an HLA-DR13 molecule. CD28, and 30 IU/ml of IL-2 . After 14 days, the growing T cell clones were screened for tumor Identification of a Gene Encoding a Nonmutated LAGE1 Protein reactivity based on the secretion of GM-CSF, a cytokine released by different types of antigen-specific T cells, We next attempted to identify the target antigen recognized by tumor-specific CD4 ϩ T cells. In previous stud-including CD4 ϩ Th1, Th2, and CD8 ϩ T cells. Thirteen tumor-reactive T cell clones were generated and further ies, we devised a genetic targeting expression system and used it to identify several MHC class II-restricted expanded. To determine the antigen specificity of T cell clones, we tested these T clones against various target tumor antigens (Wang et al., 1999a ). For this system, we generated 293ECIIDR13 cells expressing Ii, DMA, cells, including HLA-DR3 ϩ and DR13 ϩ M102 tumor cells (the HLA typing for M102 is HLA-DR3 and -DR13). Repre-DMB, and DR13 molecules as antigen-presenting cells for efficiently processing and presenting antigens to sentative data for one such CD4 ϩ T cell clone (TIL102-C4) are shown in Figure 1A , while similar results were CD4 ϩ T cells (Figure 2A) , and constructed an Ii-fusion cDNA library using mRNA isolated from M102 tumor containing 293ECIIDR13 cells transfected with LAGE1 or NY-ESO-1, and to wells seeded with M102 tumor cells. The quality of the cDNA library was evaluated by determining the size and percentage of cDNA inserts. cells. Following overnight incubation, IFN-␥ release was determined from cell supernatants. As expected, all 13 DNA library pools were prepared in 96-well format plates and were transfected into 293ECIIDR13 cells. After of the T cell clones recognized M102 tumor cells, but none recognized 293ECIIDR13 cells transfected with screening the Ii-fusion cDNA library, we identified a positive pool that stimulated T cells for increased IFN-␥ re-NY-ESO-1 ( Figure 3A) . By contrast, 10 of the 13 CD4 ϩ T cell clones recognized LAGE1. These studies suggest lease ( Figure 2B ). The positive-pool DNA was then transformed into E. coli, and individual colonies were picked that while the majority of tumor-reactive T cell clones recognize LAGE1 as the DR-13-restricted antigen, three for preparation of plasmid DNA. After rescreening of individual plasmid DNAs, we identified single cDNA T cell clones (numbers 3, 8, and 13) may recognize other unidentified tumor antigens presented by DR13 mole-clones that could stimulate T cells for cytokine release. Figure 2C shows that cDNA clones 2 and 3 were capable cules. These data also imply that the ligand for TIL102-C4 T cells resides in a region of LAGE1 with different of stimulating T cells, while cDNA clone 1 failed to activate T cells for the secretion of IFN-␥. DNA sequence amino acid sequences from NY-ESO-1. To identify T cell epitopes from LAGE1, we made two analysis and database searches revealed that both positive cDNA clones encoded the LAGE1 protein, which 13-mer peptides based on the DR13 peptide binding motif as well as amino acid differences between LAGE1 shares 94% nucleotide sequence identity with NY-ESO-1 (Chen et al., 1997; Wang et al., 1998) . LAGE1 was and NY-ESO-1, and tested their ability to stimulate T cells. Figure 3B shows that TIL102-C4 T cells recog-initially suggested as a tumor antigen on the basis of representational difference analysis (Lethe et al., 1998), nized 293ECIIDR13 cells pulsed with LAGE-P 108-120 , but not with a control peptide, LAGE-P 125-137 , containing the but MHC class II-restricted T cell epitopes from this 180 amino acid protein have not been reported. Like NY-HLA-DR13 peptide binding motif. T cell stimulation was observed at a peptide concentration of 0.1 M for seven ESO-1, LAGE1 is expressed in cancer cells and normal testis, but not in other human normal tissues. When T cell clones tested ( Figure 3C ). While TIL102-C4 and C7 T cells showed a slightly low activity, other T cell tested for their ability to recognize LAGE1 and NY-ESO-1, TIL102-C4 T cells responded to LAGE1-express-clones exhibited similar activity and affinity for the LAGE-P 108-120 peptide. ing HEK293ECIIDR13 cells, but not those expressing NY-ESO-1 ( Figure 2D ). Moreover, T cells recognized both the native and Ii-targeted forms of LAGE1, sug-TCR Usage and Cytokine Profiles of CD4 ؉ T Cell Clones gesting that the native form of LAGE1 is naturally processed and presented by HLA-DR13 molecules to We next sought to determine whether all LAGE1-specific T cell clones are the same or different clones. Twenty-CD4 ϩ T cells.
five pairs of TCR-V␤-specific primers were synthesized and used for RT-PCR amplification of RNAs isolated
Identification of the T Cell Ligand/Epitope from LAGE1
To determine the proportion of T cell clones derived from each T cell clone (McKee et al., 2000) . We found that TIL102-C1, -C2, -C4, and -C7 T cell clones shared from TIL102 that recognize NY-ESO-1 and/or LAGE1, we transfected LAGE1 and NY-ESO-1 into 293ECIIDR13 the same TCR-V␤7 gene, while TIL102-C6 and TIL102-C12 shared the same TCR-V␤6 gene. TIL102-C9, -C10, cells. We added the T cell clones individually to wells To determine peptide concentrations required for T cell recognition, 293ECIIDR13 cells were incubated with different concentrations of the LAGE-P 108-120 peptide for 90 min and then washed three times with T cell assay medium. T cells from seven different T cell clones were added to peptide-pulsed 293ECIIDR13 cells overnight. IFN-␥ release from T cells was determined with an ELISA kit. Similar results were obtained in three repeated experiments.
and -C11 T cells may differ in their TCR-V␤ usage be-
TGF-␤, while TIL102-C10 cells secreted GM-CSF, IFN-␥, and IL-10, but little or no IL-2, IL-4, or TGF-␤. To compare cause we failed to amplify any distinct band using 25 pairs of primers specific for V␤ genes, while the constant this profile with results for other CD4 ϩ effector T cells, we generated antigen-specific CD4 ϩ T cell clones (TIL1363-region was successfully amplified (data not shown). TIL102-C5 contained bands of V␤6 and V␤7 genes, sug-C1 and -C2) from TIL1363 that recognized a fusion tumor antigen, LDFP (Wang et al., 1999b) . We found that gesting that it represents a mixture of two T cell clones. Representative data from three T cell clones are shown TIL1363-C1 and -C2 CD4 ϩ T cell clones secreted IL-2, GM-CSF, and IFN-␥, but no other cytokines after stimu-in Figure 4A . The results of TCR profiling analysis led us to select TIL102-C4, -C6, and -C10 as representative lation with the 1363mel target cells ( Figure 4B ). An antigen-unspecific CD4-C5 clone derived from PBMCs of T cell clones for further analysis.
To evaluate the secretion of IL-2, IL-4, IL-10, IFN-␥, a normal donor did not respond to a tumor mixture of M102 and 1363mel cells, and served as a specificity and TGF-␤ by T cell clones, we measured cytokine release from T cell clones after coculturing with HLA-control. DR13-positive EBV-B or 293ECIIDR13 cells pulsed with the LAGE1-P 108-120 peptide for 18 hr. Representative data CD4 ؉ T Cell Clones Phenotypically Resemble CD4 ؉ Treg Cells from TIL102-C4, -C6, and -C10 T cell clones are shown in Figure 4B .
TIL102-C4 and -C6 T cells both secreted
The cytokine release profile of TIL102 CD4 ϩ T cell clones suggested that they may represent CD4 ϩ Treg cells GM-CSF, IFN-␥, IL-4, and IL-10, but little or no IL-2 or 
(A) Clonality of tumor-reactive TIL102 T cell clones by TCR profiling analysis. Total RNAs were isolated from individual TIL102 T cell clones and analyzed by RT-PCR using 25 pairs of V␤ chain-specific primers. The primers for the constant region V␤ chain were used as positive controls. Specific DNA bands amplified by PCR indicate the usage of TCR V␤ chains by TIL102 T cell clones and the purity of T cell clones. (B) Cytokine profiles of CD4 ϩ TIL102-C4, -C6, and -C10 T cells. GM-CSF, IFN-␥, IL-2, IL-4, IL-10, and TGF-␤ were determined from cell culture supernatants of T cells after coculturing with their corresponding tumor cells. TIL-1363-C1 and -C2 T cell clones were used as representatives of cytokine profiles of typical CD4 ϩ effector (Th1) T cells. CD4-C5 T cells derived from human
PBMCs were not antigen specific and served as a specificity control. Bars with Ͼ1000 pg/ml indicate that optical readings at 450 nm were higher than that of the highest level of standards (1000 pg/ml). rather than CD4 ϩ T helper cells. To test this possibility, C5 T control grown in the same condition expressed few if any CD25 or GITR molecules. When intracellular we first examined the phenotypes of CD4 ϩ TIL102 clones together with a control CD4 ϩ T cell clone (CD4-stained T cells with an antibody against CTLA4, all T cell clones were uniformly positive, but no appreciable dif-C5) by FACS analysis. Figure 5A shows that CD4 ϩ TIL102 clones were positive for CD4 ϩ , CD25, and GITR markers ferences were noted among T cell clones (data not shown). Further testing of the expression levels of CD25 more than 1 month after T cell expansion, while the CD4-
Figure 5. Phenotypic and Foxp3 Expression Analyses of CD4 ϩ TIL102 Treg Cells (A) CD4 ϩ TIL102 Treg cells and a control CD4 ϩ T cell clones from human PBMCs were stained with phycoerythrin (PE)-or FITC-labeled mAbs to CD4, CD25, and GITR molecules. An isotype antibody served as the control. All three clones of TIL102-C4, -C6, and -C10 Treg cells expressed high levels of CD4, CD25, and GITR molecules, while the control CD4-C5 T cells expressed low levels of CD25 and GITR. All FACS analyses were conducted at more than 1 month after T cell expansion. (B) Expression of CD4, CD25, and GITR molecules by antigen-specific TIL1363-C1 and -C2 T cells 2 weeks after T cell expansion. (C) Foxp3 expression by TIL102 Treg cells and antigen-specific effector/control T cells. cDNA from each T cell clone was subjected to realtime quantitative PCR analysis using primers and an internal fluorescent probe for Foxp3 or HPRT (hypoxanthine-guanine phosphoribosyltransferase). The relative quantity of Foxp3 in each T cell sample was normalized to the relative quantity of HPRT. Foxp3 expression levels in TIL102-C4, -C6, and -C10 were much higher than those in TIL1363-C1, -C2, and CD4-C5 T cells. (A) through (C) each represent one of three independent experiments. and GITR markers in antigen-specific TIL1363-C1 and
Recently, the forkhead transcription factor Foxp3 was shown to be specifically expressed by CD4 ϩ Treg cells, -C2 T cells demonstrated that like CD4-C5, these CD4 ϩ effector T cells were negative for CD25 and GITR mole- Figure 5B ). All T cell clones were maintained in the same condition and growth medium containing a ison of Foxp3 expression levels among tumor-specific CD4 ϩ TIL102 T cell clones revealed much higher levels low level of IL-2 after expansion. Thus, it appears that the CD4 ϩ TIL102-C4, -C6, and -C10 T cells express the of Foxp3 mRNA (10-fold or more) in CD4 ϩ TIL102-C4, -C6, and -C10 T cell clones than in CD4 ϩ TIL1363 and markers typically found on naturally occurring CD4 ϩ CD25 ϩ Treg cells (Shevach, 2002 . These discrepancies may reflect significantly suppressed anti-CD3-induced proliferation the use of different systems or different CD4 ϩ Treg cell in a dose-dependent manner. By contrast, we did not populations in these studies. We examined these possiobserve any suppressive activity by CD4 ϩ TIL1363 and bilities by studying tumor-specific CD4 ϩ Treg cells in a control CD4 ϩ T cell clone ( Figure 6A) , both of which the presence of various antibodies against human ILenhanced the proliferative activity of naive CD4 ϩ T cells. 10 or TGF-␤ molecules. As shown in Figure 7A , neither Taken together, these results indicate that these tumoranti-IL-10 nor anti-TGF-␤ antibody, nor both molecules specific CD4 ϩ TIL102 T cell clones can be functionally together, could block the suppressive effect of CD4 ϩ classified as CD4 ϩ Treg cells.
TIL102-C4 Treg cells on naive CD4 ϩ T cells.
To test whether cell-cell contact is required for CD4 ϩ TIL102-C4 Treg cells to exert their suppressive activity, Suppressive Activity of TIL102 Treg Cells Requires we performed transwell experiments. We first did cocul-Ligand-Specific Activation ture experiments using the same Treg cell clones We next addressed the question of whether suppressive (TIL102-C4, -C6, and -C10 clones) in parallel to make effect of CD4 ϩ regulatory TIL102 T cell clones on CD4 ϩ sure that these T cells possessed functional suppressive effector TIL1363-C1 requires ligand-specific activation.
activity. As shown in Figure 7B , when CD4 ϩ TIL102-C4, CD4 ϩ Treg cells (TIL102-C4, -C6, and -C10 T cells) were -C6, and -C10 Treg cell clones were cultured together cocultured with CD4 ϩ effector TIL1363-C1 cells in the pres-(1:1 ratio) with the naive CD4 ϩ T cells in the presence ence of the LAGE-P 108-120 peptide-pulsed 293ECIIDR13 of anti-CD3 and the purified APCs, they inhibited the cells. IL-2 secretion from TIL1363-C1 was determined proliferative activity of the naive CD4 ϩ T cells. CD4after exposure to 1363mel cells. As a control, we co-C5 T cells, by contrast, lacked the ability to inhibit the cultured TIL102 CD4 ϩ Treg cells with CD4 ϩ effector proliferative response of the naive CD4 ϩ T cells to anti-TIL1363-C1 in the presence of the LAGE-P 125-137 control CD3 antibody stimulation, regardless of the coculturing peptide-pulsed 293ECIIDR13 cells to determine the or transwell conditions. However, in transwell experispecificity and requirement for inhibition mediated by ments, CD4 ϩ TIL102-C4, -C6, and -C10 Treg cells, when TIL102-C4, -C6, and -C10 T cells. As shown in Figure 6B , cultured in the inner well containing medium with anti-IL-2 secretion by TIL1363-C1 T cells was not inhibited by CD3 and the purified APCs, did not proliferate by them-CD4 ϩ regulatory TIL102 T cells in the presence of the selves and did not inhibit the proliferative activity of LAGE-P 125-137 control peptide. However, the ability of CD4 ϩ naive T cells cultured in the outer well containing TIL1363-C1 T cells to secrete IL-2 was completely supthe same medium with anti-CD3 and the purified APCs pressed by CD4 ϩ TIL102-C4, -C6, and -C10 Treg cells ( Figure 7B ). These results demonstrate that cell-cell conactivated by the LAGE-P 108-120 peptide. These data protact is required for the T cell-mediated suppressive acvide compelling evidence that suppressive activity of tivity of CD4 ϩ Treg cells. CD4 ϩ TIL102 Treg cells requires ligand-specific activation. Because HLA-DR1-restricted TIL1363-C1 cells recognized an LDFP antigen on 1363mel cells (Wang et al., Discussion 1999b), but not 293ECIIDR13/the LAGE-P 108-120 peptide, while CD4 ϩ Treg cells recognized 293ECIIDR13/the In this study we demonstrate that antigen-specific CD4 ϩ Treg cell clones can be established from the TILs of LAGE-P 108-120 peptide, but not 1363mel cells, we conclude that recognition of antigens on the same APCs patients with cancer by the limiting dilution method. (1 ϫ 10 5 ) in the presence or absence of exogenous IL-2 (600 IU/ml). Suppressive assays were performed as above. TIL1558-C1 cells served as a control for effector T cells.
After expansion in vitro, these T cells maintained their by CD4 ϩ TIL102 Treg cells and effector T cells is not required for CD4 ϩ TIL102 Treg cells to exert its inhibitory

The proliferative activity of freshly prepared CD4 ϩ (responding) T cells (1 ϫ 10 5 ) was inhibited by different numbers of TIL102-C4, -C6, and -C-10 Treg cells in the presence of anti-CD3 antibody. Proliferation of naive CD4 ϩ T cells was assayed by adding [ 3 H]thymidine during the last 12-16 hr of culture. By contrast, CD4 ϩ TIL1363-C1 and -C2 effector cells and CD4-C5 T cells enhanced rather than suppressed the proliferative activity of responding CD4 ϩ T cells. (B) Suppression of the ability of antigen-specific CD4 ϩ effector cells to recognize tumor cells by CD4 ϩ TIL102 Treg cell clones. CD4 ϩ TIL1363-C1 T cells were coincubated with TIL102-C4, -C6, and -C10 cells, respectively, in the presence of LAGE-P 108-120 or LAGE-P 125-137 control peptides. Inhibition of the ability of TIL1363-C1 effector cells in response to 1363mel cells was determined by measuring IL-2 secretion after 18 hr coculture. TIL102-C4, -C6, and -C10 cells did not affect the ability of TIL1363-C1 to respond to 1363mel cells in the presence of a control peptide. By contrast, these CD4 ϩ Treg cell clones activated by the LAGE-P 108-120 peptide resulted in complete inhibition of the ability of 1363-C1 effector T cells to secret IL-2. Results in (A) and (B) are representative of three independent experiments. (C) Exogenous IL-2 could not reverse the suppressive activity of TIL102-C4 Treg cells. Responding CD4 ϩ T cells were cocultured with TIL102-C4 Treg cells
Figure 7. Cell-Cell Contact Is Required for T Cell Suppression by TIL102 Treg Cells
(A) Anti-IL-10, anti-TGF-␤, or both antibodies failed to block the suppressive activity of TIL102-C6 Treg cells. The suppression of proliferative activity was conducted in the presence of anti-IL-10, anti-TGF-␤, or both antibodies. The culture conditions were identical to that in Figure 6 except for the addition of antibodies to the culture. (B) Cell-cell contact is required for T cell suppression. Equal numbers of CD4 ϩ responding T cells were cultured in outer wells; TIL102 Treg T cells or CD4-C5 T cells were cultured in inner wells. Otherwise, culture conditions were identical between the inner and outer wells. To ensure that the TIL102 T cells used had suppressive activity, we used the coculture system as our positive control for the suppressive activity of TIL102 Treg cells.
Once the cells were separated with the responding CD4 ϩ T cells in the transwell system, there was no detectable suppressive activity of the responding CD4 ϩ T cells in the outer wells, regardless of the presence of TIL102 Treg, CD4-C5 T cells, or none in the inner wells. Results represent one of three independent experiments.
recent report demonstrated the generation of CD4 ϩ CD25 ϩ do not produce effector cytokines during short-term culture in vitro, while all the LAGE1-specific clones pro-Treg clones from human PBMCs, but their antigen specificity was not defined (Levings et al., 2002b) . Hence, duced large amounts of IFN-␥, IL-10, and IL-4 ( Figure  4) . The cellular origin of these regulatory T cell clones the CD4 ϩ T cell clones presented here are true tumorspecific CD4 ϩ Treg cells.
will therefore require further study. It is even possible that these clones were generated from CD25 Ϫ T cells Tumor antigen-specific regulatory T cell clones that we have isolated possess an unusual phenotype. In in vivo following interaction with naturally occurring CD4 ϩ CD25 ϩ T cells as previously described in vitro many respects they resemble the Tr1 clones described by Roncarolo et al . in that they secrete both IFN-␥ and  (Dieckmann et al., 2002; Jonuleit et al., 2002) . Regardless of the origin of these CD4 ϩ Treg cell clones, they func-IL-10 (Groux et al., 1997) . On the other hand, they suppress activation of naive T cells by a cell contact-depen-tionally suppressed the proliferation and IL-2 secretion of CD4 effector cells ( Figure 6) . dent mechanism and express FoxP3, thus resembling CD4 ϩ CD25 ϩ naturally occurring suppressor cells (Wood Very little information is available on the target antigen recognized by naturally occurring CD4 ϩ CD25 ϩ T cells. and Sakaguchi, 2003) . Another striking feature of these clones is that they maintained high level expression of Most studies in humans and experimental animals have focused on bulk CD4 ϩ Treg cells, which may display CD25 and GITR when cultured in medium containing a low level of IL-2, in contrast to effector type clones very diverse specificity. Our results suggest that it is essential to generate antigen-specific CD4 ϩ Treg clones/ cultured in the same condition which downregulated expression of these antigens (Figure 5) HLA-A, -B, -C; HB95) , were purified from American Type Lee and many pathologists at the UT MD Anderson Cancer Center Culture Collection hybridoma supernatants. 2 ϫ 10 4 irradiated tumor and Baylor College of Medicine for providing tumor samples. We cells in 80 l of T cell assay medium (RPMI 1640/10% human serum/ also thank Hoainam T. Nguyen-Jackson for her excellent technical 120 IU of IL-2) were incubated with 20 l of an antibody (200 g/ support. This work is supported in part by funds from Baylor College ml) for 30 min. 2 ϫ 10 4 T cells in 100 l T cell assay medium were of Medicine and grants from the National Cancer Institute, NIH, then added, and the mixture was incubated overnight. GM-CSF, Cancer Research Institute, and the American Cancer Society to IL-2, IL-4, IL-10, IFN-␥, and TGF-␤ release from T cells was measured R.-F.W. in culture supernatants by ELISA kits (Pierce, Rockford, IL) .
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